Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 3:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Penicillin Clear all
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis

NCT02424734
View directory record Official record
Conditions
Late-onset Sepsis
Interventions
Ceftaroline Fosamil, Ampicillin, Aminoglycoside
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Days to 59 Days
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 20, 2026, 3:51 AM EDT
Recruiting Phase 4 Interventional

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

NCT07556107
View directory record Official record
Conditions
Infection, Acute Kidney Injury, Sepsis
Interventions
Piperacillin + Tazobactam, meropenem
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Cooperstown, New York • Winston-Salem, North Carolina • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 20, 2026, 3:51 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

NCT06801223
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
Drug
Lead sponsor
Innoviva Specialty Therapeutics
Industry
Eligibility
1 Day to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 20, 2026, 3:51 AM EDT
Recruiting Phase 2 Interventional

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

NCT06406114
View directory record Official record
Conditions
Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions
Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Phase 1 Interventional

Phase I Study of Safety and Immunogenicity of ADU-623

NCT01967758
View directory record Official record
Conditions
Astrocytic Tumors, Glioblastoma Multiforme, Anaplastic Astrocytoma, Brain Tumor
Interventions
Cohort 1, Cohort 2, Cohort 3, Antibiotics
Biological · Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 20, 2026, 3:51 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Phase 4 Interventional

Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life

NCT00147914
View directory record Official record
Conditions
Acute Bacterial Sinusitis
Interventions
Cefdinir (drug), amoxicillin/clavulanate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Probiotics and Antibiotic-Associated Diarrhea

NCT04414722
View directory record Official record
Conditions
Antibiotic-associated Diarrhea
Interventions
Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, BB-12, Control Yogurt
Drug · Biological · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 20, 2026, 3:51 AM EDT
Not listed Phase 4 Interventional

Inpatient Penicillin Delabeling for Low-Risk Patients

NCT06414694
View directory record Official record
Conditions
Penicillin, Drug Allergy
Interventions
Direct Oral Challenge
Procedure
Lead sponsor
University of Tennessee
Other
Eligibility
2 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Phase 4 Interventional

NICU Antibiotics and Outcomes Trial

NCT03997266
View directory record Official record
Conditions
Microbial Colonization, Extreme Prematurity, Early-Onset Neonatal Sepsis, Late-Onset Neonatal Sepsis, Necrotizing Enterocolitis of Newborn, Death; Neonatal
Interventions
Ampicillin, Gentamycin, Normal saline
Drug
Lead sponsor
Michael Morowitz
Other
Eligibility
Up to 4 Hours
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
14
States / cities
Mobile, Alabama • San Diego, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Not applicable Interventional Results available

Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use

NCT01561703
View directory record Official record
Conditions
Snoring, Strep Throat
Interventions
Antibiotic
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Up to 17 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis

NCT03289351
View directory record Official record
Conditions
Perforated Appendicitis, Postoperative Infection
Interventions
Piperacillin, Tazobactam Drug Combination
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Phase 2 Interventional

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

NCT00002682
View directory record Official record
Conditions
Lymphoma
Interventions
Amoxicillin, Bismuth Subsalicylate, Clarithromycin, Metronidazole Hydrochloride, Omeprazole, Tetracycline Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 20, 2026, 3:51 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

NCT01756924
View directory record Official record
Conditions
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers
Interventions
CEM-102, IV or Oral standard of care antibiotics, Rifampin
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Sarasota, Florida • Tamarac, Florida • Savannah, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate

NCT02340000
View directory record Official record
Conditions
Sinusitis
Interventions
standard dose amoxicillin/clavulanate, high dose amoxicillin/clavulanate
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 20, 2026, 3:51 AM EDT
Completed No phase listed Observational Results available

Perioperative Antibiotic Choices for Surgical Prophylaxis in Penicillin-allergic Pediatric Patients

NCT02036840
View directory record Official record
Conditions
Penicillin Allergy
Interventions
Antibiotic
Drug
Lead sponsor
Joseph D. Tobias
Other
Eligibility
Not listed
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 20, 2026, 3:51 AM EDT
Recruiting Phase 2 Interventional

APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)

NCT07492134
View directory record Official record
Conditions
Acute Uncomplicated Diverticulitis
Interventions
Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, Placebo, Metronidazole, Cefuroxime
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Phase 4 Interventional

Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections

NCT00001658
View directory record Official record
Conditions
Autoimmune Disease, Mental Disorder, Obsessive Compulsive Disorder, Streptococcal Infection, Tic Disorder
Interventions
Amoxicillin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 3:51 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment

NCT06391125
View directory record Official record
Conditions
Syphilis Infection, Benzathine Penicillin Adverse Reaction
Interventions
normal Saline, Lidocaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2008 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Phase 4 Interventional Results available

Effect of Antibiotic Choice On ReNal Outcomes (ACORN)

NCT05094154
View directory record Official record
Conditions
Sepsis, AKI, Neurotoxicity
Interventions
anti-pseudomonal cephalosporin, anti-pseudomonal penicillin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2,634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Not applicable Interventional

Guidelines for Acute Sinusitis

NCT00132275
View directory record Official record
Conditions
Sinusitis
Interventions
Amoxicillin potassium clavulanate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
1 Year to 10 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Sep 20, 2026, 3:51 AM EDT
Terminated Not applicable Interventional Results available

Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients

NCT04748120
View directory record Official record
Conditions
Covid19, Appendicitis, Cholecystitis, Acute, Cholecystitis; Gallstone, Cholecystitis
Interventions
Operative management, Non-operative management
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 20, 2026, 3:51 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 20, 2026, 3:51 AM EDT